FDA Status BPC-157s FDA status remains not approved for medical use or over-the-counter sale. In April 2026, compounding restrictions were adjusted, but the peptide still cannot be prescribed or sold for human/animal consumption
Pharmacotherapy of obesity: Available medications and drugs under investigation (in Eng)
Reassess gut markers (e.g., zonulin, calprotectin) every 812 weeks under medical supervision
at Seoul National University demonstrated that AHK-Cu stimulated the elongation of human hair follicles in ex vivo organ culture, increased dermal papilla cell proliferation at picomolar to nanomolar concentrations, and upregulated vascular endothelial growth factor (VEGF) expression the growth factor most critical for perifollicular blood supply
Patients with evidence of advanced fibrosistypically identified through the ELF test (score 10.51 in adults) or other non-invasive assessmentsshould be referred to hepatology services for specialist evaluation
Computer modelling of the NAD binding site of ADP-ribosylating toxins: active-site [PMID: 1901617] Laboratory literature summary: Computer modelling of the NAD binding site of ADP-ribosylating toxins: active-site structure and mechanism of NAD binding